糖化白蛋白測定市場規模、佔有率和成長分析：按檢測法、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球糖化白蛋白檢測市場價值為 4.7079 億美元，預計到 2033 年將從 2025 年的 5.0916 億美元成長到 9.5294 億美元，在預測期（2026-2033 年）內以 8.15% 的複合年成長率。

全球糖化白蛋白（Glycated Albumin）檢測市場的主要驅動力是糖尿病盛行率的上升以及對補充傳統糖化血紅蛋白（A1c）檢測的中期血糖值評估的需求。糖化白蛋白能夠反映數週內的平均血糖值，尤其是在血紅素檢測難以準確評估血糖水平的情況下。該市場已從複雜的免疫檢測試劑盒發展到更有效率的自動化系統，反映了技術和產品開發的進步。此外，法規核准和保險報銷政策在塑造臨床實踐方面發揮著至關重要的作用，因為檢查室和診所擴大採用這些檢測方法進行胰島素調整和妊娠糖尿病監測。這種應用的增加提高了成本效益，並促使製造商開發即時檢測（POC​​）版本，從而進一步擴大了這些重要診斷工具的可近性。

全球糖化白蛋白測量市場的成長要素

全球糖化白蛋白（Glycated Albumin）檢測市場的主要促進因素之一是糖尿病及其併發症在全球範圍內的日益普遍。隨著醫療專業人員和患者尋求更準確的長期血糖控制監測方法，對糖化白蛋白檢測的需求激增。這些檢測為傳統的糖化血紅蛋白A1c檢測提供了一種可靠的替代方案，尤其是在血紅蛋白變異體可能影響檢測結果的情況下。此外，人們對有效管理糖尿病重要性的認知不斷提高，以及診斷技術的進步，都在推動糖化白蛋白檢測的普及，從而顯著促進了市場成長。

全球糖化白蛋白測量市場的限制因素

全球糖化白蛋白 (GLD) 檢測市場的主要限制因素包括缺乏標準化的檢測方案以及檢查室操作規範的區域差異。這種不一致會導致檢測結果不一致，從而可能限制 GLD 檢測的可靠性及其在醫療專業人員中的應用。此外，來自 HbA1c 等成熟生物標記的競爭以及臨床醫生對傳統方法的偏好也可能阻礙 GLD 檢測在常規臨床實踐中的應用。另外，區域醫療預算的限制也可能限制先進診斷檢測的使用，進一步阻礙市場成長。

糖化白蛋白測量的全球市場趨勢

全球糖化白蛋白 (GPI) 檢測市場正呈現顯著的趨勢，即即時檢測 (POC) 的快速發展，其特徵是分散式檢查。這一趨勢的驅動力在於門診、社區實驗室和專科醫療中心對 GPI 檢測的需求不斷成長，及時準確的檢測結果對患者管理至關重要。這些檢測的優勢在於其便利性、快速出結果以及與小型設備的兼容性，從而提高了醫護人員和患者的就醫便利性。診斷服務公司與即時檢測技術製造商之間的合作正進一步推動 GPI 檢測融入標準臨床實踐，從而鞏固其在糖尿病管理和患者照護中的作用。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球糖化白蛋白測定市場規模：依方法分類

• 酵素法
• 比色法
• 其他

全球糖化白蛋白測量市場規模：按應用領域分類。

• 糖尿病管理
• 慢性腎臟病監測
• 其他

全球糖化白蛋白測量市場規模：依最終用戶分類

• 醫院
• 診斷中心
• 研究機構

全球糖化白蛋白檢測市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Asahi Kasei
• Abbott Laboratories
• Roche Holding
• Danaher
• Siemens Energy
• Sysmex Corporation
• Thermo Fisher Scientific
• Merck KGaA
• LifeSpan BioSciences
• MyBioSource
• Cusabio Technology
• Wuhan Fine Biotech
• Bio-Rad Laboratories
• Randox Laboratories
• Diazyme Laboratories
• Abnova Corporation
• Kamiya Biomedical
• Genzyme
• DiaSys Diagnostic Systems
• Biotech Atlantic

結論與建議

Global Glycated Albumin Assay Market size was valued at USD 470.79 Million in 2024 and is poised to grow from USD 509.16 Million in 2025 to USD 952.94 Million by 2033, growing at a CAGR of 8.15% during the forecast period (2026-2033).

The global glycated albumin assay market is primarily driven by the rising prevalence of diabetes and the need for intermediate glycemic assessments to supplement traditional A1c tests. Glycated albumin offers insights into average blood sugar levels over a few weeks, especially when hemoglobin tests are not viable for accurate evaluations. The market has evolved from complex immunoassay kits to more efficient automated systems, reflecting advancements in technology and product development. Additionally, regulatory approvals and reimbursement policies play crucial roles in shaping clinical practices, as laboratories and clinics increasingly adopt these assays for monitoring insulin adjustments and gestational diabetes. This increased usage enhances cost efficiency, prompting manufacturers to develop point-of-care versions, further broadening access to these essential diagnostic tools.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glycated Albumin Assay market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glycated Albumin Assay Market Segments Analysis

Global glycated albumin assay market is segmented by method, application, end-user and region. Based on method, the market is segmented into Enzymatic Assay, Colorimetric Assay and Others. Based on application, the market is segmented into Diabetes Management, Chronic Kidney Disease Monitoring and Others. Based on end-user, the market is segmented into Hospitals, Diagnostic Centers and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glycated Albumin Assay Market

One of the key market drivers for the Global Glycated Albumin Assay Market is the increasing prevalence of diabetes and related complications worldwide. As healthcare providers and patients seek more accurate methods to monitor long-term glycemic control, the demand for glycated albumin assays has surged. These assays offer a reliable alternative to traditional hemoglobin A1c tests, especially in circumstances where hemoglobin variants may interfere with results. Furthermore, the rising awareness of the importance of managing diabetes effectively and advancements in diagnostic technologies are propelling the adoption of glycated albumin testing, thereby driving market growth significantly.

Restraints in the Global Glycated Albumin Assay Market

A significant market restraint for the global glycated albumin assay market is the lack of standardized testing protocols and variations in laboratory practices across different regions. This inconsistency can lead to discrepancies in test results, limiting the reliability and widespread adoption of glycated albumin assays among healthcare providers. Furthermore, the competition from established biomarkers like HbA1c and the preference of clinicians for more conventional methods may hinder the integration of glycated albumin tests into routine clinical practice. Additionally, healthcare budget constraints in various regions may restrict the availability of advanced diagnostic assays, further impeding market growth.

Market Trends of the Global Glycated Albumin Assay Market

The Global Glycated Albumin Assay market is experiencing a significant trend towards point-of-care expansion, characterized by a shift towards decentralized testing. This movement is driven by the increasing demand for glycated albumin tests in outpatient clinics, community laboratories, and specialty care centers, where timely and relevant results can significantly influence patient management. The appeal of these tests lies in their convenience, rapid turnaround times, and compatibility with compact devices, which enhance accessibility for both healthcare providers and patients. Collaborative efforts between diagnostic service firms and manufacturers of point-of-care technologies are further fostering the integration of glycated albumin assays into standard clinical practices, thereby solidifying their role in diabetes management and patient care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Glycated Albumin Assay Market Size by Method & CAGR (2026-2033)

• Market Overview
• Enzymatic Assay
• Colorimetric Assay
• Others

Global Glycated Albumin Assay Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diabetes Management
• Chronic Kidney Disease Monitoring
• Others

Global Glycated Albumin Assay Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes

Global Glycated Albumin Assay Market Size & CAGR (2026-2033)

• North America (Method, Application, End-User)
  • US
  • Canada
• Europe (Method, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Method, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Method, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Method, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Asahi Kasei
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Energy
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LifeSpan BioSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MyBioSource
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cusabio Technology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuhan Fine Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diazyme Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abnova Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamiya Biomedical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSys Diagnostic Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotech Atlantic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations